MA50039A - Programme de dosage pour tésétaxel et capécitabine - Google Patents
Programme de dosage pour tésétaxel et capécitabineInfo
- Publication number
- MA50039A MA50039A MA050039A MA50039A MA50039A MA 50039 A MA50039 A MA 50039A MA 050039 A MA050039 A MA 050039A MA 50039 A MA50039 A MA 50039A MA 50039 A MA50039 A MA 50039A
- Authority
- MA
- Morocco
- Prior art keywords
- tesetaxel
- capecitabine
- dosage schedule
- schedule
- dosage
- Prior art date
Links
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 title 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 title 1
- 229960004117 capecitabine Drugs 0.000 title 1
- MODVSQKJJIBWPZ-VLLPJHQWSA-N tesetaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3CC[C@@]2(C)[C@H]2[C@@H](C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C(=CC=CN=4)F)C[C@]1(O)C3(C)C)O[C@H](O2)CN(C)C)C(=O)C1=CC=CC=C1 MODVSQKJJIBWPZ-VLLPJHQWSA-N 0.000 title 1
- 229950009016 tesetaxel Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762514483P | 2017-06-02 | 2017-06-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50039A true MA50039A (fr) | 2020-07-08 |
Family
ID=64455637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050039A MA50039A (fr) | 2017-06-02 | 2018-06-01 | Programme de dosage pour tésétaxel et capécitabine |
Country Status (14)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019359755A1 (en) * | 2018-10-17 | 2021-05-20 | Odonate Therapeutics, Inc. | Methods of treating CNS tumors with tesetaxel |
| TW202112364A (zh) * | 2019-08-16 | 2021-04-01 | 美商蜻蛉治療股份有限公司 | 投與替司他賽(tesetaxel)與cyp3a4誘導劑之糖皮質素之方法 |
| WO2022177835A1 (en) * | 2021-02-16 | 2022-08-25 | Genentech, Inc. | Treatment of breast cancer using combination therapies comprising gdc-9545 and ipatasertib |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201701880A (zh) * | 2015-04-14 | 2017-01-16 | 莫瑞麥克製藥公司 | 改善持續釋放藥物治療之藥物動力學及治療指數之方法 |
-
2018
- 2018-06-01 EA EA201992852A patent/EA201992852A1/ru unknown
- 2018-06-01 MX MX2019014489A patent/MX2019014489A/es unknown
- 2018-06-01 CA CA3065783A patent/CA3065783A1/en not_active Abandoned
- 2018-06-01 BR BR112019025164-2A patent/BR112019025164A2/pt not_active Application Discontinuation
- 2018-06-01 KR KR1020207000023A patent/KR20200014880A/ko not_active Ceased
- 2018-06-01 WO PCT/US2018/035653 patent/WO2018223029A1/en not_active Ceased
- 2018-06-01 EP EP18808779.5A patent/EP3630091A4/en not_active Withdrawn
- 2018-06-01 MA MA050039A patent/MA50039A/fr unknown
- 2018-06-01 JP JP2020516788A patent/JP2020522568A/ja not_active Withdrawn
- 2018-06-01 CN CN201880041477.0A patent/CN111032035A/zh active Pending
- 2018-06-01 AU AU2018275122A patent/AU2018275122A1/en not_active Abandoned
- 2018-06-01 US US16/617,697 patent/US20200179427A1/en not_active Abandoned
- 2018-06-01 TW TW107119026A patent/TW201902473A/zh unknown
-
2019
- 2019-11-27 IL IL270973A patent/IL270973A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020522568A (ja) | 2020-07-30 |
| KR20200014880A (ko) | 2020-02-11 |
| AU2018275122A1 (en) | 2019-12-19 |
| CA3065783A1 (en) | 2018-12-06 |
| MX2019014489A (es) | 2020-08-17 |
| EA201992852A1 (ru) | 2020-03-27 |
| BR112019025164A2 (pt) | 2020-06-16 |
| WO2018223029A1 (en) | 2018-12-06 |
| US20200179427A1 (en) | 2020-06-11 |
| CN111032035A (zh) | 2020-04-17 |
| TW201902473A (zh) | 2019-01-16 |
| EP3630091A1 (en) | 2020-04-08 |
| EP3630091A4 (en) | 2021-03-10 |
| IL270973A (en) | 2020-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201902533B (en) | Anti-pd-l1 antibodies and variants | |
| IL256145B (en) | Systems and methods for patient-specific dosing | |
| EP3363816A4 (en) | ANTI-OX40 ANTIBODIES AND USES THEREOF | |
| EP3283077A4 (en) | BROMDOMÄNENINHIBITOREN | |
| EP3442972A4 (en) | BROMDOMÄNENINHIBITOREN | |
| LT3292153T (lt) | Cd30xcd16a antikūno derinys su antagonistiniu antikūnu prieš pd-1 skirtas terapijai | |
| EP3728925A4 (en) | DOUBLE PIPE FITTING AND INSTALLATION OF A DOUBLE PIPE FITTING | |
| PT3362477T (pt) | Proteínas de ligação a antigénio que ativam o recetor de leptina | |
| EP3565174C0 (en) | ACCESS MANAGEMENT SYSTEM, ACCESS MANAGEMENT METHOD AND PROGRAM | |
| IL258024A (en) | Composition and method for treating complement-mediated disease | |
| GB201708624D0 (en) | System for evaluating dosage parameters | |
| EP3664029A4 (en) | IMAGE PROCESSING DEVICE, IMAGE PROCESSING METHOD AND PROGRAM | |
| EP3411302A4 (en) | HOPPER COVER | |
| EP3611701A4 (en) | IMAGE PROCESSING DEVICE, IMAGE PROCESSING METHOD AND PROGRAM | |
| EP3586627A4 (en) | Mouse catching box | |
| EP3683214A4 (en) | BRD4 INHIBITOR | |
| EP3569151A4 (en) | IMAGE PROCESSING DEVICE, IMAGE PROCESSING METHOD, AND PROGRAM | |
| EP3385719A4 (en) | DEVICE FOR TURNING OBJECTS | |
| EP3526210A4 (en) | BROMDOMAIN INHIBITORS | |
| IL270973A (en) | Dosing schedule for testaxel and capecitabine | |
| EP3598374A4 (en) | RELAY DEVICE AND PROGRAM | |
| FR3032925B1 (fr) | Generation et traitement deporte de photometrie | |
| DK3456736T3 (da) | Antistofvarianter | |
| EP3526197A4 (en) | BROMDOMAIN INHIBITORS | |
| EP3734431A4 (en) | PICTURE PANORAMIC CREATION PROCESS |